BIOMAT Database Logo BIOMAT Database Logo

Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis. 1983

N J Dodd, and M P Gordge, and M J Weston

1 We have assessed the thromboxane synthetase inhibitor, dazoxiben (UK 37248), during dialysis in a double-blind, placebo-controlled crossover study. 2 Thromboxane generation was markedly inhibited, and there was an increase in serum 6-keto prostaglandin F1 alpha levels during active treatment studies. 3 We were unable to demonstrate any reduction of platelet activation, or dialyser fibrin deposition, nor were heparin requirements altered by the drug. 4 Dazoxiben had no adverse effects.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013929 Thromboxane B2 A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). B2, Thromboxane
D013930 Thromboxane-A Synthase An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2

Related Publications

N J Dodd, and M P Gordge, and M J Weston
Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon.
July 1984, Clinical pharmacology and therapeutics,
N J Dodd, and M P Gordge, and M J Weston
SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
February 1984, Thrombosis and haemostasis,
N J Dodd, and M P Gordge, and M J Weston
Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome.
June 1985, Chest,
N J Dodd, and M P Gordge, and M J Weston
Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben.
July 1988, Prostaglandins, leukotrienes, and essential fatty acids,
N J Dodd, and M P Gordge, and M J Weston
Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.
January 1983, British journal of clinical pharmacology,
N J Dodd, and M P Gordge, and M J Weston
Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
December 1982, European journal of pharmacology,
N J Dodd, and M P Gordge, and M J Weston
CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
January 1987, European journal of pharmacology,
N J Dodd, and M P Gordge, and M J Weston
Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor.
January 1983, British journal of clinical pharmacology,
N J Dodd, and M P Gordge, and M J Weston
The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
October 1983, Thrombosis and haemostasis,
N J Dodd, and M P Gordge, and M J Weston
Use of a novel thromboxane synthetase inhibitor in burns.
June 1987, Burns, including thermal injury,
Copied contents to your clipboard!